Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Gary A. Lyons sold 5,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $84.67, for a total value of $423,350.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded down $0.67 during mid-day trading on Tuesday, hitting $84.58. The stock had a trading volume of 506,175 shares, compared to its average volume of 1,024,921. The firm has a market cap of $7,480.00, a P/E ratio of -51.89 and a beta of 0.26. The company has a current ratio of 10.20, a quick ratio of 10.20 and a debt-to-equity ratio of 0.99. Neurocrine Biosciences, Inc. has a 1-year low of $39.21 and a 1-year high of $91.82.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The firm had revenue of $94.52 million during the quarter, compared to analyst estimates of $94.00 million. During the same period last year, the firm posted ($0.51) EPS. equities analysts forecast that Neurocrine Biosciences, Inc. will post -0.11 earnings per share for the current year.
Several research analysts have weighed in on NBIX shares. Jefferies Group boosted their price target on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a report on Friday, January 5th. BMO Capital Markets boosted their price target on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Oppenheimer set a $85.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, December 12th. Needham & Company LLC reiterated a “buy” rating and issued a $86.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Leerink Swann reiterated an “outperform” rating and issued a $83.00 price target (up from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Neurocrine Biosciences currently has a consensus rating of “Buy” and an average price target of $88.79.
Several hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its holdings in shares of Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after buying an additional 193 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Neurocrine Biosciences by 0.7% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after buying an additional 810 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Neurocrine Biosciences by 5.7% during the 4th quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock worth $1,357,000 after buying an additional 947 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Neurocrine Biosciences by 25.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock worth $458,000 after buying an additional 1,200 shares during the last quarter. Finally, Grandfield & Dodd LLC increased its holdings in shares of Neurocrine Biosciences by 24.1% during the 3rd quarter. Grandfield & Dodd LLC now owns 7,610 shares of the company’s stock worth $466,000 after buying an additional 1,480 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Director Sells 5,000 Shares of Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/20/insider-selling-neurocrine-biosciences-inc-nbix-director-sells-5000-shares-of-stock.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.